COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD

Earlier in July 2026, COMPASS Pathways reported 26-week data from its second Phase 3 COMP006 trial of COMP360 psilocybin in treatment-resistant depression, showing rapid onset, durable clinical benefit and a generally well-tolerated safety profile, while advancing a rolling New Drug Application with the FDA toward a potential 2027 launch. The company also published a post-hoc analysis from a Phase 2 PTSD study indicating that patients’ improvements appeared to arise mainly from the...

- Earlier in July 2026, COMPASS Pathways reported 26-week data from its second Phase 3 COMP006 trial of COMP360 psilocybin in treatment-resistant depression, showing rapid onset, durable clinical benefit and a generally well-tolerated safety profile, while advancing a rolling New Drug Application with the FDA toward a potential 2027 launch. - The company also published a post-hoc analysis from a Phase 2 PTSD study indicating that patients' improvements appeared to arise mainly from the psilocybin experience itself, supported by minimal, non-directive monitoring rather than traditional psychotherapy. - We'll now examine how these Phase 3 durability results for COMP360 could reshape COMPASS Pathways' investment narrative and long-term business outlook.

Uncover the next big thing with 20 elite penny stocks that balance risk and reward. COMPASS Pathways Investment Narrative Recap To own COMPASS Pathways, you have to believe COMP360 can clear late stage trials, secure FDA approval and translate into real world TRD use before cash constraints bite. The new 26 week COMP006 data directly support the key near term catalyst, the rolling NDA, but regulatory timing, launch costs and any safety or efficacy surprises still look like the biggest swing factors for the business.

The most relevant update here is the COMP006 Part B readout, which showed 39% of patients on 25 mg achieving clinically meaningful MADRS improvement by week 6 and maintaining benefit through week 26, with generally manageable side effects. These data, alongside the ongoing NDA submission, strengthen the clinical package feeding into that regulatory decision, while the PTSD post hoc analysis hints at a potentially more scalable, less psychotherapy heavy delivery model if COMP360 reaches the market. Yet, against this progress, the risk that additional financing could be needed if NDA review or launch timing slips is something investors should be aware of... COMPASS Pathways' narrative projects $284.9 million revenue and $53.9 million earnings by 2029.

This requires an earnings increase of about $246 million from -$192.4 million today. Uncover how COMPASS Pathways' forecasts yield a $24.47 fair value, a 97% upside to its current price. Exploring Other Perspectives Before this news, the most cautious analysts were only penciling in about US$59.5 million of revenue and US$6.5 million of earnings by 2029, and they worry that any restrictive label or REMS style controls could limit how much of the promising COMP360 data actually converts into real world treatment volumes and profits.